Spark gene therapy improves vision, at least in short term: FDA – Reuters
Kansas City Star |
Spark gene therapy improves vision, at least in short term: FDA
Reuters (Reuters) – Spark Therapeutics Inc’s experimental gene therapy for a rare inherited form of blindness improves vision, though it is unclear whether the benefit lasts over time, according to a preliminary review by the U.S. Food and Drug Administration. Correction: Genetic Frontiers-Blindness-Gene Therapy story The FDA is Considering a Landmark Approval of Gene Therapy To Cure Blindness Seeing hope: FDA panel considers gene therapy for blindness |
View original article
Author: